The innovation capabilities of local pharmaceutical companies continue to improve, and domestic new drugs are accelerating their advancement into medical insurance

Recently, in the announced 2021 National Medical Insurance Drug List, 74 new drugs have been added to the list and 11 drugs have been removed from the list
.
Seven non-exclusive drugs are directly imported, and 67 drugs are included through negotiation
.
Among them, it is worth noting that many of the drugs entering the medical insurance this time are innovative drugs of pharmaceutical companies, covering cardiovascular, tumor, rare diseases and other fields
.
According to the analysis, a batch of Class 1 new drugs from Hengrui Pharmaceuticals, BeiGene, Betta Pharmaceuticals, Zejing Pharmaceuticals, Alice and other companies entered for the first time, and many of them were approved for listing during the year
.
For example, 9 products of Hengrui Medicine are included in the national medical insurance catalogue, among which, the three new Class 1 drugs of Hytropopamine Tablets, Fluzoparil Capsules, and Remazolam Tosylate for Injection are included in the National Medical Insurance Catalogue for the first time
.
In addition, Zejing Pharmaceutical's oral multi-target, multi-kinase inhibitor small molecule anti-tumor drug Donafenib tosylate tablets, and Iris' EGFR (epidermal growth factor receptor tyrosine kinase) inhibitor A Many Class 1 new drugs such as vomitinib sulfonate tablets, Aidi Pharmaceuticals’ HIV infection antiviral drug Ainovirin tablets, and Hisun Pharmaceutical’s oral intestinal cholesterol absorption inhibitor Haibo Mebu tablets, etc.
are also Included for the first time
.
In addition, many innovative drugs of multinational pharmaceutical companies have also entered this medical insurance
.
For example, Roche Pharmaceuticals China has five innovative drugs-Sufuda® (Mabaloxavir), Jialuohua® (Otuzumab), Anvastin® (bevacizumab), Ansheng Through this medical insurance adjustment, Shasa® (Aletinib) and Pertuzumab® (Pertuzumab) are on the list in the new version of the National Medical Insurance Catalogue
.
At the same time, Novartis, Eli Lilly, Sanofi, etc.
all have products and new indications in this catalog, many of which are also innovative drugs that fill the "blank"
.
From the above comprehensive point of view, the analysis believes that, compared with the past 8 years of non-adjustment of medical insurance catalogues, more and more domestically-made new drugs are entering medical insurance with the smooth flow of "routine actions"; it can be clearly seen that domestic pharmaceutical companies Innovation capabilities have been significantly improved, and the medical insurance access of domestic innovative drugs is not only predictable, but the access cycle is also greatly shortened, and the speed in all aspects is further accelerated.

.
Affected by this, the industry expects that more domestic new drugs will be included in the future, and as more new drugs will be included, especially new anti-tumor drugs continue to enter medical insurance through negotiations, the level of domestic drug protection will be significantly improved, and medications will be available.
Sexuality will also be further improved, benefiting more patients
.
It is worth mentioning that the new version of the medical insurance catalog will be formally implemented from January 1 next year.
From the current point of view, medical insurance departments in various regions are intensively carrying out information system adjustments, policy linkages, and personnel training, and strive to negotiate drugs as soon as possible
.
In this regard, some industry insiders have analyzed and suggested that after the drug enters the medical insurance catalog, it may also be expected to accelerate the volume of pharmacy products through the "dual channel" mechanism
.